June 28, 2010 06:19 ET
QIAGEN Wins 2010 Mediscience Award for "Transaction of the Year"
KJ VENLO, GERMANY--(Marketwire - June 28, 2010) -
Qiagen N.V. / QIAGEN Wins 2010 Mediscience Award for "Transaction of the
Year" processed and transmitted by Hugin AS. The issuer is solely
responsible for the content of this announcement.
Jury recognizes strategic initiative to expand leadership position in
Germantown, MD and Hilden, Germany, June 28, 2010 --- QIAGEN's
DxS Ltd. was recognized as the "Transaction of the Year" at this
Mediscience Awards, the largest annual gathering of publicly quoted
biotech and life science companies in Europe, held in London.
In September 2009, QIAGEN acquired the personalized healthcare company DxS
known today as QIAGEN Manchester. DxS had created what may be the
portfolio of pharma partnerships in molecular companion diagnostics
the diagnostic component of personalized healthcare. Its partners include
AstraZeneca, Bristol-Myers Squibb, Boehringer Ingelheim, Pfizer and others.
The acquisition of DxS added to QIAGEN's rapidly expanding menu of
companion diagnostic tests a portfolio of molecular diagnostic
intellectual property, as well as a deep pipeline of companion
oncology. Most of this portfolio is in development with partners,
seven of the largest drug makers in this field. These assets complement
existing strong portfolio of personalized healthcare diagnostic
are very synergistic with QIAGEN's sample and assay technologies.
The transaction was valued at approximately US$ 95 million in cash
customary purchase price adjustments), plus up to an additional US$ 35
if specified commercial and other milestones are met.
"The purchase of DxS was an important strategic step for QIAGEN. It
to build a leadership position in personalized healthcare, which is
most transformational area of today's healthcare. The transaction
strategy of driving molecular diagnostics across all segments:
profiling, personalized healthcare and point of need", said Ulrich Schriek,
President Business Development at QIAGEN. "DxS brought to QIAGEN
pharma partnerships and experienced professionals which made a great
our team and to our diagnostic capabilities. The combination can
leverage tremendous opportunities and expand our leadership position in
rapidly emerging field."
On behalf of the voting panel, Kate Silverton, BBC News anchor and
presenter, said: "QIAGEN has been highly acquisitive during the past 18
but it's most important deal was the September 2009 acquisition of DxS Ltd.
this acquisition QIAGEN has added a strong leadership position in the new
David Wilson, Chief Executive of Piper Jaffray, the lead sponsors of the
said: "Congratulations to the winners, we salute each and every one of
winners have been the stars of 2010, working in challenging
responding by adapting themselves for future growth."
Personalized healthcare approaches are based on patients' molecular
already play an increasingly important role for the treatment of
and neurological diseases and - most prominently - cancer. The
molecular markers for various therapies and indications has been
steadily. Today, there are already 32 genomic biomarkers identified by
the context of FDA-approved drug labels. In the last ten years the
personalized healthcare drugs exceeded US$ 13 billion, reflecting a CAGR of
QIAGEN N.V., a Netherlands holding company, is the leading global
sample and assay technologies. Sample technologies are used to
process DNA, RNA and proteins from biological samples such as
tissue. Assay technologies are used to make such isolated bio-molecules
QIAGEN has developed and markets more than 500 sample and assay products as
as automated solutions for such consumables. The company provides its
to molecular diagnostics laboratories, academic researchers,
biotechnology companies, and applied testing customers for purposes
forensics, animal or food testing and pharmaceutical process control.
assay technologies include one of the broadest panels of molecular
tests available worldwide. This panel includes the digene HPV Test,
regarded as a "gold standard" in testing for high-risk types of
papillomavirus (HPV), the primary cause of cervical cancer, as well as a
suite of solutions for infectious disease testing and companion
QIAGEN employs more than 3,500 people in over 30 locations worldwide.
information about QIAGEN can be found athttp://www.qiagen.com/.
Certain of the statements contained in this news release may be
forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the U.S.
Exchange Act of 1934, as amended. To the extent that any of the
contained herein relating to QIAGEN's products, markets, strategy or
results are forward-looking, such statements are based on current
that involve a number of uncertainties and risks. Such uncertainties and
include, but are not limited to, risks associated with management of
international operations (including the effects of currency
risks of dependency on logistics), variability of operating
commercial development of the applied testing markets, clinical research
and proteomics markets, nucleic acid-based molecular diagnostics
genetic vaccination and gene therapy markets, competition, rapid or
changes in technologies, fluctuations in demand for QIAGEN's,
(including fluctuations due to the level and timing of customers'
budgets, and other factors), our ability to obtain regulatory approval
infectious disease panels, difficulties in successfully adapting
products to integrated solutions and producing such products, the
QIAGEN to identify and develop new products and to differentiate its
from competitors' products, market acceptance of QIAGEN's new products
integration of acquired technologies and businesses. For further
refer to the discussions in reports that QIAGEN has filed with, or
the U.S. Securities and Exchange Commission (SEC).
Public Relations Investor Relations
Dr. Thomas Theuringer Dr. Solveigh Maehler
Director Public Relations Director Investor Relations
+49 2103 29 11826 +49 2103 29 11710
Email:firstname.lastname@example.org Albert F. Fleury
Investor Relations North America
+1 301 944 7028
--- End of Message ---
Spoorstraat 50 KJ Venlo Netherlands
Listed: Freiverkehr in Börse Stuttgart,
Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
Freiverkehr in Börse Berlin,
Freiverkehr in Börse Düsseldorf,
Freiverkehr in Bayerische Börse München,
Freiverkehr in Niedersächsische Börse zu Hannover,
Prime Standard in Frankfurter Wertpapierbörse;
This announcement is distributed by Thomson Reuters on behalf of Thomson
Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other
applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality
of the information contained therein.
All reproduction for further distribution is prohibited.
Source: Qiagen N.V. via Thomson Reuters ONE